ADMA Biologics Study Shows Optimized IVIG Process Removes Impurities Linked to Thrombosis Risk

ADMA Biologics announced publication of peer-reviewed findings on its optimized intravenous immune globulin manufacturing process in Frontiers in Cardiovascular Medicine. Testing of three commercial-scale lots showed effective removal of impurities linked to thrombosis risk while preserving immunoglobulin quality. The FDA-licensed optimized process increased immunoglobulin yield without compromising product integrity. No thromboembolic events were reported for products manufactured using the process during surveillance from July 1, 2025, through July 31, 2026. Limited testing and potential underreporting prevent conclusions that risk is absent; thrombosis remains a labeled risk for ASCENIV and BIVIGAM. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via (Ref. ID: 202610150700PRIMZONEFULLFEED9846267) on October 15, 2026, and is solely responsib